Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial

References

• Kavannagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia. Drugs 2002;62:743–55
   PubMed Web of Science ®Google Scholar
• Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23:717–34
   Google Scholar
• Soyka M, De Vry J. Flupenthixol as a potential pharmaco-treatment of alcohol and cocaine abuse/dependence. Eur Neuropsychopharmacol 2000;10:325–32
   PubMed Web of Science ®Google Scholar
• Wise R, Bozarth M. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469–92
   PubMed Web of Science ®Google Scholar
• Brady K, Anton R, Ballenger JC, et al. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990;147:1164–7
   PubMed Web of Science ®Google Scholar
• Green AI, Salomon MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Target CNS Neurol Disord 2002;1:129–39
   PubMedGoogle Scholar
• Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441–9
   PubMed Web of Science ®Google Scholar
• Cheer SM, Wagstaff AJ. Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 2004;18:173–99
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2003;27:1159–72
   PubMed Web of Science ®Google Scholar
• Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406–11
   PubMed Web of Science ®Google Scholar
• Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 2003;23:384–8
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 2004;49: 711
   Google Scholar
• Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Rev Psychiatry 1997;4:231–44
   PubMed Web of Science ®Google Scholar
• Stip E, Fahim C, Mancini-Marië A, et al. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2005;29:21–6
   Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457–72
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518–26
   PubMed Web of Science ®Google Scholar
• Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatr Neurosci 2001;26:137–49
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, et al., for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371–6
   Google Scholar
• Leucht S, Pitschel-Walz G, Kissling AW. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51–68
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76
   Google Scholar
• Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alchol Clin Exp Res 1999;23:1289–95
   PubMed Web of Science ®Google Scholar
• Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption; in: Littren RZ, Allen JP, editors. Measuring alcohol consumptions: psychosocial and biochemical methods. Towota: Humana Press, 1992, pp.41–72
   Google Scholar
• Drake RE, Osher FC, Noordsy DL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990;16:57–67
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201–8
   PubMed Web of Science ®Google Scholar
• Chouinard G, Ross-Chouinard A, Annabale L, et al. The extra-pyramidal symptoms rating scale. Can J Neurol Sci 1980;7:233
   Web of Science ®Google Scholar
• Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–6
   PubMed Web of Science ®Google Scholar
• Elliott R, McKenna PJ, Robbins TW, et al. Specific neuro-psychological deficits in schizophrenic patients with preserved intellectual function. Cogn Neuropsychiatry 1998;3:45–70
   Google Scholar
• Stip E, Caron S, Renaud T, et al. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry 2003;44:331–40
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999;13:358–71
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642–52
   PubMed Web of Science ®Google Scholar
• Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 2002;36:229–40
   PubMed Web of Science ®Google Scholar
• Buckley PF. Efficacy of quetiapine for treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004;20:1357–63
   PubMed Web of Science ®Google Scholar
• Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265–73
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1–93
   PubMed Web of Science ®Google Scholar
• Wolford GL, Rosenberg SD, Oxman TE, et al. Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychol Addict Behav 1999;13:313–26
   Web of Science ®Google Scholar
• Carey KB, Cocco KM, Simons JS. Concurrent validity of clinicians’ ratings of substance abuse among psychiatric out-patients. Psychiatr Serv 1996;47:842–7
   Google Scholar
• Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizoph Res 2004;66:115–24
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42: 233–46
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al., and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997;54:549–57
   Google Scholar
• Fray PJ, Robbins TW, Sahakian BJ. Neuropsychiatric applications of CANTAB. Int J Geriatr Psychiatr 1996;11:329–36
   Web of Science ®Google Scholar